Glaucoma is a generic term for eye diseases that include an increase in intraocular pressure. This pressure damages the optic nerve and is the most common cause of blindness. More than two million Americans over the age of 35 have developed glaucoma, and 300,000 new cases of the disease are recorded every year.
It was found that cannabis is able to reduce intraocular pressure, but when taking cannabis, patients experience side effects, regardless of whether it is administered orally, by injection or while smoking. These side effects include increased heart rate, increased blood pressure, and psychological effects. Some of them take place under the extensive effects of cannabis.
The mechanism by which cannabis reduces eye pressure remains unknown. Cannabis is believed to dilate blood vessels that drain fluids from the eyeball. It is believed that such drainage prevents the concentration of fluid and as a result, pressure does not occur, resulting in damage to the optic nerve.
Clinical studies of the potential benefits of cannabis for treating glaucoma continue in two main areas. The first is the development of synthetic formulas that would eliminate side effects. The second direction concerns methods of application. Particular attention is paid to the development of a drug that can be injected directly into the eye.
.Nausea and vomiting
Cannabis and synthetic THC are used to prevent nausea and vomiting, often caused by chemotherapy (and radiation treatment) of cancer. These side effects, which can last from several hours to several days, are often not mitigated by traditional antiemetic drugs.
Researchers in the 1970s began a systematic study of the anti-emetic effects of TNS, which led to good results. The study was initiated after stories of chemotherapy patients who reported using marijuana on their own to mitigate the side effects of this treatment.
Positive results continue to appear in subsequent studies. Moreover, there is evidence that the effects of chemotherapy treatment for children’s cancer can be partially eliminated by taking oral doses of cannabinoids. More recent research concerns the use of artificially created TNS, such as Nabinole. The main obstacle to the use of cannabis and artificial THS is that they have the mental effects that some patients have experienced. This is discomfort and anxiety. However, many patients treated with chemotherapy consider the side effects of HNS not so serious. Research in this area is likely to advance if a decision is made by the Drug Distribution Authority (DEA) to reclassify synthetic THC into a Group 2 drug (see Appendix N1), which means awareness of its particular medical value. Synthetic THC was originally classified as Group N1 drugs, that is, treated as drugs with no medical value. Marijuana is still a drug of Group N1.